# Neurocrine Biosciences

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/neurocrine-biosciences
Canonical HTML page: https://getbiobrief.com/entity/neurocrine-biosciences

## Timeline

- **2026-03**: Q4 2025 Earnings — Both companies report full-year 2025 results and 2026 guidance.
- **2025-Q3**: Olpruva Scaling — Zevra reports steady growth in urea cycle disorder market share.
- **2025**: Novartis Expansion — Voyager expands its capsid discovery collaboration with Novartis.
- **2024-Q4**: Miplyffa Approval — Zevra receives FDA approval for arimoclomol in NPC treatment.

## Recent coverage (1 stories)

### Voyager and Zevra Set for Q4 Earnings Amid Commercial and Pipeline Shifts
2026-03-08 22:53:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Full story: https://getbiobrief.com/story/voyager-zevra-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.